{"id":"https://openalex.org/W4220848121","doi":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09","title":"Abstract P2-08-09: Investigation of autoantibodies (AAbs) in HER2+ breast cancer (BC) patients treated in the neo-adjuvant setting","display_name":"Abstract P2-08-09: Investigation of autoantibodies (AAbs) in HER2+ breast cancer (BC) patients treated in the neo-adjuvant setting","publication_year":2022,"publication_date":"2022-02-15","ids":{"openalex":"https://openalex.org/W4220848121","doi":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs21-p2-08-09","doi":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029977513","display_name":"Denis Martin Collins","orcid":"https://orcid.org/0000-0003-1043-6169","observed_orcids":["https://orcid.org/0000-0003-1043-6169"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Denis Martin Collins","raw_affiliation_strings":["Dublin City University, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dublin City University, Dublin, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062705888","display_name":"Ji Qiu","orcid":"https://orcid.org/0000-0002-7913-9042","observed_orcids":["https://orcid.org/0000-0002-7913-9042"]},"institutions":[{"id":"https://openalex.org/I55732556","display_name":"Arizona State University","ror":"https://ror.org/03efmqc40","country_code":"US","type":"education","lineage":["https://openalex.org/I55732556"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ji Qiu","raw_affiliation_strings":["Arizona State University, Tempe, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arizona State University, Tempe, AZ;","institution_ids":["https://openalex.org/I55732556"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033442365","display_name":"Jaine K. Blayney","orcid":"https://orcid.org/0000-0001-5618-5284","observed_orcids":["https://orcid.org/0000-0001-5618-5284"]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jaine Blayney","raw_affiliation_strings":["Queen's University Belfast, Belfast, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Belfast, United Kingdom","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072702884","display_name":"Nuala McCabe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nuala McCabe","raw_affiliation_strings":["Queen's University Belfast, Belfast, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Belfast, United Kingdom","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088266020","display_name":"Richard D. Kennedy","orcid":"https://orcid.org/0000-0003-4737-6163","observed_orcids":["https://orcid.org/0000-0003-4737-6163"]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Richard Kennedy","raw_affiliation_strings":["Queen's University Belfast, Belfast, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Belfast, United Kingdom","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046993686","display_name":"Joshua LaBaer","orcid":"https://orcid.org/0000-0001-5788-9697","observed_orcids":["https://orcid.org/0000-0001-5788-9697"]},"institutions":[{"id":"https://openalex.org/I55732556","display_name":"Arizona State University","ror":"https://ror.org/03efmqc40","country_code":"US","type":"education","lineage":["https://openalex.org/I55732556"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua LaBaer","raw_affiliation_strings":["Arizona State University, Tempe, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arizona State University, Tempe, AZ;","institution_ids":["https://openalex.org/I55732556"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043292277","display_name":"John Paul Crown","orcid":"https://orcid.org/0000-0002-3125-7613","observed_orcids":["https://orcid.org/0000-0002-3125-7613"]},"institutions":[{"id":"https://openalex.org/I4210115218","display_name":"St. Vincent's University Hospital","ror":"https://ror.org/029tkqm80","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210115218"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"John Crown","raw_affiliation_strings":["Saint Vincent's University Hospital, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Vincent's University Hospital, Dublin, Ireland","institution_ids":["https://openalex.org/I4210115218"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"4_Supplement","first_page":"P2","last_page":"08"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9419999718666077},{"id":"https://openalex.org/keywords/tumor-associated-autoantibodies","display_name":"tumor-associated autoantibodies","score":0.9419999718666077},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.7960000038146973},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9359999895095825},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.7829999923706055},{"id":"https://openalex.org/keywords/nucleic-acid-programmable-protein-arrays","display_name":"nucleic acid programmable protein arrays","score":0.8610000014305115},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8769999742507935},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.7459999918937683},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.6600000262260437},{"id":"https://openalex.org/keywords/serum-autoantibodies","display_name":"serum autoantibodies","score":0.5370000004768372}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.8112894296646118},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7829526662826538},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7136561870574951},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6178369522094727},{"id":"https://openalex.org/C163764329","wikidata":"https://www.wikidata.org/wiki/Q785022","display_name":"Autoantibody","level":3,"score":0.6013429760932922},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5367845892906189},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5247775912284851},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5160291194915771},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.46398523449897766},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4471304416656494},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.4425988495349884},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.4333984851837158},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.42525768280029297},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4167240858078003},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3901885449886322},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38695165514945984},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35328245162963867},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2702100872993469}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs21-p2-08-09","doi":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs21-p2-08-09","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7154480394","https://openalex.org/W3083427786","https://openalex.org/W3121227538","https://openalex.org/W2531685605","https://openalex.org/W1530219086","https://openalex.org/W3031090766","https://openalex.org/W2806692351","https://openalex.org/W2595012392","https://openalex.org/W39346709","https://openalex.org/W1820106848"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"HER2+":[2,125,149,297,337,359,388,420],"breast":[3,126,150,298,338,421],"cancer":[4,127,151,299,339,422],"is":[5,70,390],"treated":[6,128,154,163,425],"with":[7,86,164,367],"anti-HER2":[8],"IgG":[9,87,207,244,260,286],"monoclonal":[10],"antibody":[11],"therapies":[12],"such":[13],"as":[14,29,187,237,383],"trastuzumab":[15,171],"and":[16,24,44,88,95,110,121,140,208,246,277,319,331,347,370],"pertuzumab.":[17],"These":[18],"antibodies":[19],"inhibit":[20],"HER2-driven":[21],"intracellular":[22],"signaling":[23],"can":[25,55],"also":[26],"be":[27,56],"described":[28],"a":[30,74,189,195,201,220,238,393],"form":[31],"of":[32,73,92,112,222,232,380,385,396,416,433],"passive":[33],"immunotherapy,":[34],"engaging":[35],"effector":[36],"immune":[37,61,82],"cells":[38],"in":[39,65,80,124,129,252,345,351,374,387,392,419,426],"antibody-dependent":[40,45],"cell-mediated":[41,46],"cytotoxicity":[42],"(ADCC)":[43],"phagocytosis":[47],"(ADCP).":[48],"Tumor-associated":[49],"autoantibodies":[50,417],"(AAbs)":[51,418],"to":[52,84,115,205,270,275,281,295,312,317,323,335,376],"tumor":[53],"neo-antigens":[54],"generated":[57],"by":[58,264,306],"the":[59,81,98,108,130,156,215,427,434],"adaptive":[60],"response":[62,66,83,192,197,369,375,386],"before,":[63,119],"or":[64,175,200],"to,":[67],"therapy.":[68],"There":[69],"growing":[71],"evidence":[72],"functional":[75],"role":[76],"for":[77,240],"tumor-associated":[78],"AAbs":[79,90,114,245,249,261,268,273,279,287,303,310,315,321,329,342,365],"tumors,":[85],"IgA":[89,209,248,302,328],"capable":[91],"mediating":[93],"ADCC":[94],"ADCP.":[96],"Using":[97],"innovative":[99],"Nucleic":[100],"Acid-Programmable":[101],"Protein":[102],"Array":[103],"(NAPPA)":[104],"platform":[105],"we":[106],"examined":[107],"levels":[109,211,372,382],"targets":[111],"circulating":[113,364],"~1700":[116],"human":[117,225],"proteins":[118],"during":[120],"after":[122],"treatment":[123,349,368],"neo-adjuvant":[131,165,428],"setting.":[132],".":[133],"Methods:":[134],"Pre-treatment,":[135],"On-treatment":[136,346],"(pre-":[137],"Cycle":[138],"2)":[139],"Post-treatment":[141],"(post-Cycle":[142],"6)":[143],"serum":[144],"samples":[145,350],"were":[146,162,185,212,250,262,283,293,304,325,333,343],"obtained":[147],"from":[148],"patients":[152,353,361,424],"(n=19)":[153],"on":[155,219],"ICORG":[157],"10-05":[158],"clinical":[159],"trial.":[160],"Patients":[161,184],"chemotherapy":[166],"(docetaxel":[167],"(T)/carboplatin":[168],"(C))":[169],"+/-":[170],"(H),":[172],"lapatinib":[173],"(L)":[174],"HL,":[176],"TCH":[177],"n=9,":[178],"TCHL":[179],"n=":[180],"7,":[181],"TCL":[182],"n=3.":[183],"classified":[186],"having":[188],"pathological":[190],"complete":[191],"(pCR,":[193],"n=6),":[194],"partial":[196],"(PR,":[198],"n=6)":[199],"non-response":[202],"(NR,":[203],"n=7)":[204],"treatment.":[206,377],"autoantibody":[210],"determined":[213],"using":[214],"HD-NAPPA":[216],"system,":[217],"focussing":[218],"subset":[221],"~":[223],"1700":[224],"protein":[226],"targets.":[227],"A":[228],"normalised":[229],"intensity":[230],"score":[231],">":[233],"5":[234,285],"was":[235],"utilised":[236],"cut-off":[239],"detection.":[241],"Results:":[242],"92":[243],"29":[247],"detected":[251,344],"all":[253,256,296,336],"samples,":[254],"across":[255],"timepoints":[257],"(n=57).":[258],"When":[259,301],"divided":[263,305],"patient":[265,307],"response,":[266,308],"26":[267,272],"unique":[269,274,280,311,316,322,363],"pCR,":[271,313],"PR":[276,318],"16":[278],"NR":[282,324],"detected.":[284,326],"(BCL11B,":[288],"MAP6,":[289],"PRDM8,":[290],"SYTL2,":[291],"TP53BP2)":[292],"common":[294,334],"patients.":[300,340,397],"11":[309],"6":[314],"7":[320],"2":[327],"(TDP1":[330],"MAP6)":[332],"Treatment-induced":[341],"Post-":[348],"16/19":[352],"examined.":[354],"Conclusions:":[355],"Our":[356],"results":[357],"suggest":[358],"BC":[360,389],"have":[362],"associated":[366],"AAb":[371,381],"change":[373],"Further":[378],"investigation":[379],"biomarkers":[384],"warranted":[391],"larger":[394],"cohort":[395],"Citation":[398],"Format:":[399],"Denis":[400],"Martin":[401],"Collins,":[402],"Ji":[403],"Qiu,":[404],"Jaine":[405],"Blayney,":[406],"Nuala":[407],"McCabe,":[408],"Richard":[409],"Kennedy,":[410],"Joshua":[411],"LaBaer,":[412],"John":[413],"Crown.":[414],"Investigation":[415],"(BC)":[423],"setting":[429],"[abstract].":[430],"In:":[431],"Proceedings":[432],"2021":[435,441],"San":[436,444],"Antonio":[437],"Breast":[438],"Cancer":[439,450],"Symposium;":[440],"Dec":[442],"7-10;":[443],"Antonio,":[445],"TX.":[446],"Philadelphia":[447],"(PA):":[448],"AACR;":[449],"Res":[451],"2022;82(4":[452],"Suppl):Abstract":[453],"nr":[454],"P2-08-09.":[455]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-04-03T00:00:00"}